Check out our most popular compounded medications! Get Started
Mesalamine 250 mg Slow Release Capsules are compounded with Methocel E4M, a controlled-release polymer. This formulation is designed to gradually release the active ingredient over an extended period, providing sustained therapeutic effects and improved patient compliance due to reduced dosing frequency. These capsules are used in the treatment of Ulcerative Colitis, Crohn's Disease, Proctitis, Proctosigmoiditis, and Diverticulitis.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Mesalamine 250 mg Slow Release Capsules are a specialized compounded formulation designed to treat various inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. This prescription medication is formulated with Methocel E4M, a type of controlled-release polymer. This innovative design allows for the gradual release of the encapsulated mesalamine over an extended period, providing sustained therapeutic effects.
The slow and sustained release of mesalamine from these capsules allows for a more consistent therapeutic effect, reducing the risk of side effects associated with higher doses of the medication. This formulation also offers the advantage of reduced dosing frequency, which can lead to improved patient compliance, particularly for medications requiring a controlled and prolonged release profile.
Mesalamine 250 mg Slow Release Capsules are taken orally, typically once a day. It is crucial to take this medication exactly as prescribed by your healthcare provider. Do not alter the prescribed dose without consulting your doctor. To minimize the risk of stomach upset, it is recommended to take this medication with food or a full glass of water.
This medication works by reducing inflammation in the bowel, thereby improving symptoms associated with ulcerative colitis and Crohn's disease. However, like all medications, Mesalamine 250 mg Slow Release Capsules can cause side effects. Common side effects include nausea, vomiting, diarrhea, and headache. If you experience any of these or other side effects, it is important to contact your healthcare provider immediately.
If you have any questions or concerns about Mesalamine 250 mg Slow Release Capsules, please do not hesitate to contact us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide you with the information and support you need.
Mesalamine 250 mg Slow Release Capsules are a specialized formulation designed for the treatment of mild to moderate ulcerative colitis, proctitis, and proctosigmoiditis. This medication is also utilized to prevent the recurrence of ulcerative colitis. The active ingredient, Mesalamine, functions by reducing inflammation in the colon and rectum, providing relief from these conditions.
The capsules are formulated with Methocel E4M, a type of controlled-release polymer. This technology allows for the gradual release of the encapsulated medication over an extended period of time. This sustained release offers prolonged therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly for medications requiring a controlled and prolonged release profile.
It is crucial to take Mesalamine 250 mg Slow Release Capsules as prescribed by your healthcare provider. Do not alter the recommended dose, and do not discontinue the medication without consulting your doctor. This medication may interact with other drugs, including antacids, antibiotics, and sulfa drugs. Therefore, it is important to inform your doctor about all medications, vitamins, and herbal supplements you are currently taking.
Mesalamine 250 mg Slow Release Capsules may cause side effects such as nausea, vomiting, stomach pain, headache, and dizziness. If you experience any of these side effects, it is important to contact your healthcare provider immediately.
If you have any questions or concerns about Mesalamine 250 mg Slow Release Capsules, do not hesitate to reach out to your healthcare provider or pharmacist for further information and guidance.
Mesalamine 250 mg Slow Release Capsules are a specialized formulation designed to treat conditions such as ulcerative colitis, proctitis, and proctosigmoiditis. The active ingredient, mesalamine, is an anti-inflammatory drug that targets inflammation in the lining of the colon and rectum. The unique feature of these capsules is the incorporation of Methocel E4M, a controlled-release polymer. This polymer is designed to gradually release the encapsulated medication over an extended period, providing sustained therapeutic effects.
The slow release formulation of Mesalamine 250 mg Capsules allows for a more consistent therapeutic effect, reducing the frequency of dosing and potentially improving patient compliance, particularly for medications requiring a controlled and prolonged release profile. It is recommended that these capsules be taken with food and swallowed whole without crushing, chewing, or breaking them.
Patients should adhere to the prescribed dosage of Mesalamine 250 mg Slow Release Capsules as determined by their healthcare provider. The dosage and duration of treatment are typically based on the severity of the condition being treated. It is crucial to follow the medication regimen as directed and not to discontinue the medication without consulting a healthcare provider.
Common side effects of Mesalamine 250 mg Slow Release Capsules may include nausea, vomiting, headache, and abdominal pain. Patients experiencing severe side effects or those that persist should seek medical attention. Healthcare providers prescribing Mesalamine 250 mg Slow Release Capsules should consider the patient's medical history and concurrent medications. Monitoring the patient's response to the medication and adjusting the dosage as necessary is also important.
If you have any questions or concerns about Mesalamine 250 mg Slow Release Capsules, please consult with your healthcare provider for further information and guidance.
Mesalamine 250 mg Slow Release Capsules is a medication used to treat certain bowel diseases. It is formulated with Methocel E4M, a type of controlled-release polymer, designed to release the encapsulated medication gradually over an extended period of time.
The controlled-release polymer, Methocel E4M, is designed to gradually release the medication over an extended period of time. This offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance for medications requiring a controlled and prolonged release profile.
The slow release of Mesalamine provides sustained therapeutic effects, meaning the medication continues to work over a longer period of time. This reduces the need for frequent dosing, which can improve patient compliance with their medication regimen.
'Improved patient compliance' refers to the likelihood of a patient correctly following their prescribed medication regimen. A medication with a slow release formulation, like Mesalamine 250 mg Slow Release Capsules, can improve compliance by reducing the frequency of doses required.
A 'prolonged release profile' refers to the characteristic of a medication to be released and absorbed into the body over an extended period of time. This is achieved through the use of controlled-release polymers like Methocel E4M in the formulation of the medication.
Methocel E4M is a type of controlled-release polymer used in the formulation of certain medications. It is designed to gradually release the encapsulated medication over an extended period of time, providing sustained therapeutic effects.
The frequency of dosing will depend on your specific medical condition and your doctor's instructions. However, the slow release formulation is designed to reduce the frequency of dosing compared to traditional medications.
No, you should not break or chew the capsules. Doing so can interfere with the controlled-release mechanism and may result in too much of the drug being released at once.
If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
Like all medications, Mesalamine 250 mg Slow Release Capsules can have side effects. Common side effects may include headache, nausea, or mild abdominal discomfort. If you experience any severe or persistent side effects, you should contact your healthcare provider immediately.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
